Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, Guangxi 530200, China.
Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, Guangxi 530200, China.
Curr Drug Metab. 2024;25(5):340-354. doi: 10.2174/0113892002299923240801092101.
Sakurasosaponin, a primary bioactive saponin from Aegiceras corniculatum, shows potential as an anti-cancer agent. However, there is a lack of information on its in vivo metabolism. This study aims to profile the in vivo metabolites of sakurasosaponin in rat feces, urine, and plasma after oral administration. An efficient strategy using ultra-high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry was developed, which combined metabolic prediction, multiple mass defects filtering, and highresolution extracted ion chromatograms for rapid and systematic analysis.
Firstly, a theoretical list of metabolites for sakurasosaponin was developed. This was done by considering the metabolic pathways of saponins. Next, the multiple mass defects filtering method was employed to identify potential metabolites in feces and urine, using the unique metabolites of sakurasosaponin as multiple mass defects filtering templates. Subsequently, a high-resolution extracted ion chromatogram was used to quickly determine the metabolites in rat plasma post-identification in feces and urine. Lastly, the analysis of accurate mass, typical neutral loss, and diagnostic ion of the candidate metabolites was carried out to confirm their structural elucidation, and metabolic pathways of sakurasosaponin in vivo were also proposed.
In total, 30 metabolites were provisionally identified in feces, urine, and plasma. Analysis of metabolic pathways revealed isomerization, deglycosylation, oxidation, hydroxylation, sulfate conjugation, glucuronide conjugation, and other related reactions as the primary biotransformation reactions of sakurasosaponin in vivo.
The findings demonstrate that the designed research strategy effectively minimizes matrix interference, prevents the omission of low-concentration metabolites, and serves as a foundation for the discovery of active metabolites of sakurasosaponin.
樱花皂苷是桐花树的主要生物活性皂苷,具有抗癌作用。然而,其体内代谢信息尚缺乏。本研究旨在通过口服给药,对樱花皂苷在大鼠粪便、尿液和血浆中的体内代谢物进行谱分析。采用超高效液相色谱/四极杆飞行时间质谱联用,建立了一种有效的策略,该策略结合代谢预测、多重质量亏损过滤和高分辨提取离子色谱图,用于快速系统地分析。
首先,根据皂苷的代谢途径,建立了樱花皂苷的代谢产物理论预测列表。然后,采用多重质量亏损过滤方法,利用樱花皂苷的独特代谢产物作为多重质量亏损过滤模板,对粪便和尿液中的潜在代谢产物进行鉴定。接下来,使用高分辨提取离子色谱图对粪便和尿液中鉴定出的代谢物进行快速确证。最后,对候选代谢物的精确质量、典型中性丢失和诊断离子进行分析,以确定其结构阐明,并提出樱花皂苷在体内的代谢途径。
共在粪便、尿液和血浆中鉴定出 30 种代谢产物。代谢途径分析表明,体内樱花皂苷的主要生物转化反应包括异构化、去糖基化、氧化、羟化、硫酸酯化、葡萄糖醛酸苷化和其他相关反应。
研究结果表明,设计的研究策略有效地减少了基质干扰,避免了低浓度代谢物的遗漏,为樱花皂苷的活性代谢物的发现奠定了基础。